Application 203313
- Type
- BLA
- Sponsor
- NOVO
Purple Book Biologic Products#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 203313 | Ryzodeg 70/30 | insulin degludec and insulin aspart | 351(a) | Disc | 2026-08-01 |
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | RYZODEG 70/30 | INSULIN ASPART; INSULIN DEGLUDEC | SOLUTION;SUBCUTANEOUS | 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML) | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.